HOLX - Hologic, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
44.87
-0.20 (-0.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close45.07
Open44.75
Bid44.89 x 2900
Ask45.49 x 800
Day's Range44.75 - 45.29
52 Week Range37.47 - 48.82
Volume1,138,574
Avg. Volume1,626,063
Market Cap12.027B
Beta (3Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Kahn Brothers Trims New York Times, Hologic Positions
    GuruFocus.com11 days ago

    Kahn Brothers Trims New York Times, Hologic Positions

    Founded in 1978, Kahn Brothers (Trades, Portfolio) & Co. Inc. currently manages more than $800 million in assets. Warning! GuruFocus has detected 3 Warning Sign with BOM:532772. The trade had an impact of -2.24% on the portfolio.

  • Markit12 days ago

    See what the IHS Markit Score report has to say about Hologic Inc.

    Hologic Inc NASDAQ/NGS:HOLXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for HOLX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $8.24 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents16 days ago

    Edited Transcript of HOLX earnings conference call or presentation 1-May-19 8:30pm GMT

    Q2 2019 Hologic Inc Earnings Call

  • Cramer Remix: Why buybacks have not benefited Bed Bath & Beyond
    CNBC17 days ago

    Cramer Remix: Why buybacks have not benefited Bed Bath & Beyond

    Jim Cramer explains how the retailer has hurt itself by spending fortunes buying back stock.

  • Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall
    Zacks17 days ago

    Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall

    Hologic (HOLX) registers solid Q1year-over-year revenue growth in core businesses like Breast Health and Molecular Diagnostics.

  • Hologic Inc (HOLX) Q2 2019 Earnings Call Transcript
    Motley Fool18 days ago

    Hologic Inc (HOLX) Q2 2019 Earnings Call Transcript

    HOLX earnings call for the period ending March 30, 2019.

  • Hologic (HOLX) Beats Q2 Earnings and Revenue Estimates
    Zacks18 days ago

    Hologic (HOLX) Beats Q2 Earnings and Revenue Estimates

    Hologic (HOLX) delivered earnings and revenue surprises of 1.75% and 1.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press18 days ago

    Hologic: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Marlborough, Massachusetts-based company said it had a loss of $1.01. Earnings, adjusted for non-recurring costs, came to 58 cents per share. The results beat Wall Street expectations. ...

  • Benzinga18 days ago

    Hologic's Q2 Earnings Preview

    Hologic (NASDAQ: HOLX ) releases its next round of earnings this Wednesday, May 1. Here's Benzinga's essential guide to Hologic's second-quarter earnings report. Earnings and Revenue Wall Street expects ...

  • Hologic (HOLX) Earnings Expected to Grow: Should You Buy?
    Zacks25 days ago

    Hologic (HOLX) Earnings Expected to Grow: Should You Buy?

    Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • How Financially Strong Is Hologic, Inc. (NASDAQ:HOLX)?
    Simply Wall St.last month

    How Financially Strong Is Hologic, Inc. (NASDAQ:HOLX)?

    Hologic, Inc. (NASDAQ:HOLX), a large-cap worth US$13b, comes to mind for investors seeking a strong and reliable stock investment. One reason being its ‘too big to fail’ aura which gives it the appearance of a strong and stable inv...

  • Double Top Spells Trouble for 3 Health Care Stocks
    Investopedialast month

    Double Top Spells Trouble for 3 Health Care Stocks

    Health care stocks have fallen out of favor due to sector rotation and political pressure. Explore three trading ideas to benefit from falling prices.

  • Hologic's Diagnostics Grows Strong, Escalating Costs a Woe
    Zackslast month

    Hologic's Diagnostics Grows Strong, Escalating Costs a Woe

    To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.

  • Were Hedge Funds Right About Flocking Into Hologic, Inc. (HOLX)?
    Insider Monkeylast month

    Were Hedge Funds Right About Flocking Into Hologic, Inc. (HOLX)?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • Here's Why You Should Invest in ResMed (RMD) Stock Right Now
    Zacks2 months ago

    Here's Why You Should Invest in ResMed (RMD) Stock Right Now

    ResMed (RMD) continues to invest and expand presence in high-growth markets like China, South Korea, India, Brazil and many countries in Eastern Europe.

  • Genomic Health's New Positive Data to Boost Test Uptake
    Zacks2 months ago

    Genomic Health's New Positive Data to Boost Test Uptake

    Genomic Health (GHDX) continues to see positive developments for Oncotype DX Breast Recurrence Score tests.

  • Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
    Zacks2 months ago

    Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock

    The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerates IDEXX's (IDXX) recurring CAG Diagnostics revenue growth.

  • Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3
    Zacks2 months ago

    Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3

    Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.

  • Zimmer Biomet's FDA 510(k) Nod Widens Robotic Offerings
    Zacks2 months ago

    Zimmer Biomet's FDA 510(k) Nod Widens Robotic Offerings

    With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.

  • Here's Why You Should Invest in Genomic Health (GHDX) Now
    Zacks2 months ago

    Here's Why You Should Invest in Genomic Health (GHDX) Now

    Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.

  • Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm
    Zacks2 months ago

    Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm

    Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.

  • National Vision (EYE) Rides on Positive Comps Amid Cost Woes
    Zacks2 months ago

    National Vision (EYE) Rides on Positive Comps Amid Cost Woes

    National Vision (EYE) has been witnessing positive comps owing to increased customer transaction over the last 68 sequential quarters.

  • Hologic CEO: Preventing false positives with 3D mammography technology
    CNBC17 days ago

    Hologic CEO: Preventing false positives with 3D mammography technology

    Hologic CEO Stephen MacMillan explains to Jim Cramer how the company is using technology to address challenges in women's health.